Erkan Baloglu

5.4k total citations
85 papers, 3.0k citations indexed

About

Erkan Baloglu is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Erkan Baloglu has authored 85 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Molecular Biology, 41 papers in Oncology and 11 papers in Hematology. Recurrent topics in Erkan Baloglu's work include Nuclear Structure and Function (26 papers), Cancer-related Molecular Pathways (20 papers) and RNA Research and Splicing (12 papers). Erkan Baloglu is often cited by papers focused on Nuclear Structure and Function (26 papers), Cancer-related Molecular Pathways (20 papers) and RNA Research and Splicing (12 papers). Erkan Baloglu collaborates with scholars based in United States, Singapore and Belgium. Erkan Baloglu's co-authors include David G. I. Kingston, William Senapedis, Yosef Landesman, Sharon Shacham, Dilara McCauley, Michael Kauffman, Claudio Festuccia, Giovanni Luca Gravina, Prakash G. Jagtap and Marsha Crochiere and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Blood.

In The Last Decade

Erkan Baloglu

83 papers receiving 2.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Erkan Baloglu United States 30 1.9k 1.2k 346 319 298 85 3.0k
Chunrong Yu United States 33 2.2k 1.2× 669 0.6× 566 1.6× 184 0.6× 222 0.7× 49 3.0k
Alexander R. Shoemaker United States 19 2.2k 1.2× 906 0.8× 233 0.7× 332 1.0× 336 1.1× 22 3.0k
Shingo Dan Japan 26 1.4k 0.7× 493 0.4× 184 0.5× 278 0.9× 149 0.5× 95 2.3k
Tomoko Oh‐hara Japan 31 2.0k 1.0× 1.7k 1.4× 142 0.4× 237 0.7× 182 0.6× 65 3.4k
Harshani R. Lawrence United States 35 2.1k 1.1× 1.3k 1.1× 182 0.5× 369 1.2× 683 2.3× 75 3.5k
Longchuan Bai United States 32 2.7k 1.4× 1.2k 1.0× 469 1.4× 363 1.1× 421 1.4× 68 3.5k
Sally Przybranowski United States 16 1.8k 0.9× 757 0.6× 267 0.8× 316 1.0× 278 0.9× 24 2.5k
Małgorzata Czyż Poland 32 2.0k 1.0× 847 0.7× 121 0.3× 452 1.4× 448 1.5× 112 3.2k
Volker Gekeler Germany 35 3.0k 1.6× 2.0k 1.7× 186 0.5× 225 0.7× 405 1.4× 88 4.6k
Olivier Sordet France 36 3.3k 1.8× 1.2k 1.0× 186 0.5× 213 0.7× 384 1.3× 52 4.0k

Countries citing papers authored by Erkan Baloglu

Since Specialization
Citations

This map shows the geographic impact of Erkan Baloglu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erkan Baloglu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erkan Baloglu more than expected).

Fields of papers citing papers by Erkan Baloglu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erkan Baloglu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erkan Baloglu. The network helps show where Erkan Baloglu may publish in the future.

Co-authorship network of co-authors of Erkan Baloglu

This figure shows the co-authorship network connecting the top 25 collaborators of Erkan Baloglu. A scholar is included among the top collaborators of Erkan Baloglu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erkan Baloglu. Erkan Baloglu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Khan, Husain Yar, Misako Nagasaka, Amro Aboukameel, et al.. (2023). Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRAS G12C-Mutant Pancreatic and Lung Cancers. Molecular Cancer Therapeutics. 22(12). 1422–1433. 5 indexed citations
2.
Uddin, Md. Hafiz, Mohammed Najeeb Al Hallak, Amro Aboukameel, et al.. (2021). PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus. Molecular Cancer Therapeutics. 20(10). 1836–1845. 16 indexed citations
3.
Bhatnagar, Bhavana, Sanjay Mohan, William Senapedis, et al.. (2019). Eltanexor (KPT-8602), a Second-Generation Selective Inhibitor of Nuclear Export (SINE) Compound, in Patients with Higher-Risk Myelodysplastic Syndrome. Blood. 134(Supplement_1). 2997–2997. 4 indexed citations
4.
Aboukameel, Amro, Irfana Muqbil, Steve Kim, et al.. (2019). PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors. Cancers. 11(12). 1902–1902. 24 indexed citations
5.
Khan, Husain Yar, Misako Nagasaka, Amro Aboukameel, et al.. (2019). Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance. International Journal of Molecular Sciences. 21(1). 237–237. 30 indexed citations
6.
7.
Neggers, Jasper E., Tim Dierckx, Hiroki Noguchi, et al.. (2018). Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes. Nature Communications. 9(1). 502–502. 78 indexed citations
8.
Chien, Wenwen, Makoto Sudo, Ling‐Wen Ding, et al.. (2018). Functional Genome-wide Screening Identifies Targets and Pathways Sensitizing Pancreatic Cancer Cells to Dasatinib. Journal of Cancer. 9(24). 4762–4773. 28 indexed citations
9.
Hays, John L., Jordan Berlin, Mark H. O’Hara, et al.. (2018). Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic colorectal cancer (mCRC). Annals of Oncology. 29. viii716–viii716. 3 indexed citations
10.
Takao, Sumiko, Wenwen Chien, Vikas Madan, et al.. (2017). Targeting the vulnerability to NAD+ depletion in B-cell acute lymphoblastic leukemia. Leukemia. 32(3). 616–625. 30 indexed citations
11.
Zhou, Xia, Xiaonan Chen, Josephine F. Trott, et al.. (2017). Anticystogenic activity of a small molecule PAK4 inhibitor may be a novel treatment for autosomal dominant polycystic kidney disease. Kidney International. 92(4). 922–933. 10 indexed citations
12.
Aboukameel, Amro, Irfana Muqbil, William Senapedis, et al.. (2016). Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma. Molecular Cancer Therapeutics. 16(1). 76–87. 74 indexed citations
13.
Aboud, Omran Abu, Ching‐Hsien Chen, William Senapedis, et al.. (2016). Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth. Molecular Cancer Therapeutics. 15(9). 2119–2129. 115 indexed citations
14.
Vercruysse, Thomas, Jolien De Bie, Jasper E. Neggers, et al.. (2016). The Second-Generation Exportin-1 Inhibitor KPT-8602 Demonstrates Potent Activity against Acute Lymphoblastic Leukemia. Clinical Cancer Research. 23(10). 2528–2541. 53 indexed citations
15.
Azmi, Asfar S., Irfana Muqbil, Jack Wu, et al.. (2015). Targeting the Nuclear Export Protein XPO1/CRM1 Reverses Epithelial to Mesenchymal Transition. Scientific Reports. 5(1). 16077–16077. 29 indexed citations
16.
Senapedis, William, Marsha Crochiere, Erkan Baloglu, & Yosef Landesman. (2015). Therapeutic Potential of Targeting PAK Signaling. Anti-Cancer Agents in Medicinal Chemistry. 16(1). 75–88. 31 indexed citations
17.
Senapedis, William, Erkan Baloglu, & Yosef Landesman. (2014). Clinical translation of nuclear export inhibitors in cancer. Seminars in Cancer Biology. 27. 74–86. 99 indexed citations
18.
Senapedis, William, Dilara McCauley, Marsha Crochiere, et al.. (2014). Novel Selective Orally Bioavailable Small Molecule PAK4 Allosteric Modulators (PAMs) Display Anti-Tumor Activity in Vitro and in Vivo in Hematological Malignancies. Blood. 124(21). 2208–2208. 2 indexed citations
19.
Baloglu, Erkan, et al.. (2004). Synthesis and biological evaluation of novel taxoids designed for targeted delivery to tumors. Bioorganic & Medicinal Chemistry Letters. 14(23). 5885–5888. 15 indexed citations
20.
Baloglu, Erkan, Jeannine Hoch, Sabarni K. Chatterjee, et al.. (2003). Synthesis and biological evaluation of C-3′NH/C-10 and C-2/C-10 modified paclitaxel analogues. Bioorganic & Medicinal Chemistry. 11(7). 1557–1568. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chunrong Yu Breakdown of academic impact, for papers by Alexander R. Shoemaker Breakdown of academic impact, for papers by Shingo Dan Breakdown of academic impact, for papers by Tomoko Oh‐hara Breakdown of academic impact, for papers by Harshani R. Lawrence Breakdown of academic impact, for papers by Longchuan Bai Breakdown of academic impact, for papers by Sally Przybranowski Breakdown of academic impact, for papers by Małgorzata Czyż Breakdown of academic impact, for papers by Volker Gekeler Breakdown of academic impact, for papers by Olivier Sordet
Rankless by CCL
2026